683 Capital Management’s SELLAS Life Sciences SLS Stock Holding History

683 Capital Management’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-66,000	Closed	-$400K	–	179
2019 Q3	$400K	Sell	66,000 -6,500	-9%	-$47.9K	0.04%	101
2019 Q2	$408K	Buy	72,500 +47,000	+184%	+$1.67M	0.04%	117
2019 Q1	$1.3M	Sell	25,500 -12,500	-33%	-$869K	0.12%	88
2018 Q4	$2.34M	Buy	38,000 +12,500	+49%	+$968K	0.14%	84
2018 Q3	$1.56M	Buy	+25,500	New	+$1.76M	0.1%	89

Other funds holding SLS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Leap Investments Chicago, Illinois $152M AUM 3.6% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

683 Capital Management's SLS Position: Q4 2019 in Review

683 Capital Management sold out of SELLAS Life Sciences (SLS) in Q4 2019, closing a stake of 66,000 shares — an estimated $400K sold.

683 Capital Management first reported a position in SLS in Q3 2018 and held it in 5 quarters. The position peaked at $2.34M in Q4 2018. 11 funds tracked by Wall St. Rank hold SLS as of Q4 2019.

683 Capital Management reported no remaining SELLAS Life Sciences position as of Q4 2019 after selling out during the quarter.
683 Capital Management sold 66,000 SELLAS Life Sciences shares in Q4 2019, an estimated $400K.
683 Capital Management first reported a position in SELLAS Life Sciences in Q3 2018 and held it in 5 quarters.
683 Capital Management's SELLAS Life Sciences position peaked at $2.34M in Q4 2018.
11 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q4 2019.

Based on 683 Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.